BioWorld

Nov. 1, 2002

Zonagen's Search For Merger Partner Ends With Lavipharm

Zonagen Inc., searching for ways to benefit shareholders for some time, said it is merging with Lavipharm Corp. in a move that should please Zonagen stockholders and fulfill Lavipharm's desire to become a public company. (BioWorld Today) Read More

Embryo Joins Ranks Of Human Subjects Requiring Protection

A Newly Discovered Bacterium Lays Low Trichloroethane, A Worldwide Industrial Pollutant

SuperGen Plans Orathecin NDA Following Consultation With FDA

Cerus Gets $50M Loan Pledge From Intercept Partner Baxter

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...